China Biologic Products Holdings, Inc. (CBPO) Financial Statements (2025 and earlier)

Company Profile

Business Address 18TH FL, JIALONG INTERNATIONALBUILDING
BEIJING, 100125
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments197,357183,766203,204204,034180,117182,970
Cash and cash equivalents197,357183,766203,204204,034180,117144,938
Short-term investments      38,033
Receivables51,64833,91946,17938,25930,59325,145
Inventory, net of allowances, customer advances and progress billings166,380156,413146,936136,038130,877126,395
Inventory166,380156,413146,936136,038130,877126,395
Deposits current assets  1,0001,0384,90110,30810,056
Deferred tax assets  3,954   3,225
Other undisclosed current assets17,73214,32137,51621,58721,66321,321
Total current assets:433,118393,372434,873404,819373,558369,113
Noncurrent Assets
Property, plant and equipment138,038132,092134,424126,418115,501105,364
Long-term investments and receivables55,06553,86054,54053,82054,97448,552
Long-term investments11,58310,6159,6158,5808,5438,718
Accounts and financing receivable, after allowance for credit loss43,48243,24544,92545,24046,43139,834
Other noncurrent assets5,8382,2442,2102,4463,1994,861
Deferred tax assets, net  672    
Other undisclosed noncurrent assets23,36322,71824,19724,22824,93223,576
Total noncurrent assets:222,304211,585215,372206,912198,607182,354
TOTAL ASSETS:655,422604,958650,246611,731572,165551,466
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,96213,64317,64415,21514,22114,193
Taxes payable9,3917,48410,4908,6908,2274,511
Accounts payable6,5706,1597,1556,5265,9959,682
Debt8,696     
Other undisclosed current liabilities59,64859,79854,75349,27742,62757,463
Total current liabilities:84,30673,44172,39864,49256,84871,655
Noncurrent Liabilities
Liabilities, other than long-term debt10,25810,38010,88611,71811,12312,849
Deferred revenue and credits3,6553,7564,0264,1804,4204,526
Other liabilities6,6026,6246,8597,5386,7038,323
Total noncurrent liabilities:10,25810,38010,88611,71811,12312,849
Total liabilities:94,56483,82183,28376,21067,97184,505
Equity
Equity, attributable to parent502,780462,201475,945442,608415,237382,343
Common stock333333
Treasury stock, value(56,425)(56,425)(56,425)(56,425)(56,425)(56,425)
Additional paid in capital113,630105,460125,123117,265109,649105,080
Accumulated other comprehensive income (loss)(22,903)(25,320)(11,801)(8,889)2,108(19)
Retained earnings468,475438,483419,046390,654359,901333,704
Equity, attributable to noncontrolling interest58,07858,93691,01792,91288,95784,619
Total equity:560,858521,137566,962535,520504,193466,962
TOTAL LIABILITIES AND EQUITY:655,422604,958650,246611,731572,165551,466

Income Statement (P&L) ($ in thousands)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
Revenues91,45377,63586,52691,42185,58868,285
Cost of revenue(32,215)(30,862)(27,647)(31,482)(34,043)(27,022)
Gross profit:59,23846,77358,87959,93951,54441,263
Operating expenses(20,422)(23,510)(19,156)(16,904)(13,650)(18,291)
Other undisclosed operating loss      (399)
Operating income:38,81623,26339,72343,03537,89422,573
Nonoperating income2,4734,2652,8301,4631,446957
Investment income, nonoperating1,6242,9071,8661,2921,7511,324
Interest and debt expense(63)(20)(58)(89)(89)(193)
Income from continuing operations before equity method investments, income taxes:41,22727,50942,49544,41039,25223,337
Income (loss) from equity method investments  2,519   (174)
Other undisclosed income (loss) from continuing operations before income taxes63(2,499)588989367
Income from continuing operations before income taxes:41,28927,52842,55244,49839,34023,530
Income tax expense(6,951)(4,348)(7,164)(7,007)(6,607)(3,201)
Income from continuing operations:34,33823,18035,38937,49232,73320,330
Income before gain (loss) on sale of properties:34,33823,18035,38937,49232,73320,330
Net income:34,33823,18035,38937,49232,73320,330
Net loss attributable to noncontrolling interest(4,347)(3,742)(6,997)(6,739)(6,536)(4,050)
Net income attributable to parent:29,99219,43828,39130,75326,19716,280
Undistributed earnings (loss) allocated to participating securities, basic 
Other undisclosed net loss available to common stockholders, basic (983)(673)(889)(775)(648)(2,071)
Net income available to common stockholders, basic:29,00918,76527,50329,97825,54914,209
Other undisclosed net income available to common stockholders, diluted      1,657
Net income available to common stockholders, diluted:29,00918,76527,50329,97825,54915,866

Comprehensive Income ($ in thousands)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
Net income:34,33823,18035,38937,49232,73320,330
Other comprehensive income     2 
Other undisclosed comprehensive income (loss)2,721(17,062)(3,544)(13,267)2,568(9,273)
Comprehensive income:37,0596,11831,84524,22435,30311,057
Comprehensive loss, net of tax, attributable to noncontrolling interest(4,651)(1,214)(6,366)(4,469)(6,979)(2,396)
Comprehensive income, net of tax, attributable to parent:32,4094,90525,47919,75628,3248,661

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: